Ampliphi Biosciences (APHB) Stock Price, News & Analysis

Company Overview

AmpliPhi Biosciences Corporation was a clinical-stage biotechnology company focused on developing bacteriophage therapies for bacterial infections, particularly infections caused by antibiotic-resistant pathogens. Bacteriophages are naturally occurring viruses that selectively infect and destroy bacteria, offering a potential alternative or complement to conventional antibiotics.

The company developed a proprietary phage-discovery and development platform and advanced product candidates including AP-PA01, an investigational therapy targeting Pseudomonas aeruginosa infections, and AP-SA02, which targeted Staphylococcus aureus. Its research was directed toward serious respiratory and systemic infections, including conditions affecting patients with cystic fibrosis and other vulnerable populations.

AmpliPhi operated as a development-stage biotechnology company serving the pharmaceutical and healthcare markets through its research and clinical programs rather than through commercial products. In 2019, the company changed its name to Armata Pharmaceuticals, Inc. and continued its bacteriophage development activities under that identity. Todd R. Patrick served as chief executive officer during AmpliPhi’s transition to Armata.

Key Stats

• Today's Range: $3.43 to $3.77
• 50-Day Range: $2.78 to $5.84
• 52-Week Range: $0.15 to $1.37
• Volume: 64,051 shs
• Average Volume: 842,200 shs
• Market Capitalization: $125.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:APHB
• Previous Symbol: AMEX:APHB
• CIK: 921114
• Web: www.ampliphibio.com
• Phone: +1-804-8272524
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,469,000
• Free Float: N/A
• Market Cap: $125.51 million
• Optionable: Not Optionable
• Beta: N/A